By Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The Life Science Industry needs a strong, predictable, reliable patent system that incentivizes innovations in order to bring new drugs and diagnostics to the patient, drives innovations and prevents patent abuse. The US Supreme Court has rendered a series of decisions about patent eligibility (§101 of the Patent Act) that make entire parts of Life Science Technology ineligible for patent protection and/or renders granted patents unenforceable. This makes the patent system unreliable and unpredictable and averse to investment into innovations. Change will need to come from Congress. Recently, a group of Senators and Representatives of the US Congress released the draft text of a bipartisan, bicameral proposal to reform Section 101 of the Patent Act. The initiative to reform Section 101 of the Patent Act needs political support from all life science stakeholders including from those in Biotech.
New CEO for Valo Therapeutics
AppointmentsValo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.
Healthier and sustainable food ingredients from biotech
OpinionAs food producers are taking up current health and sustainability trends more and more, the next EFIB (30 September??2 October, 2019) will see a lot of technology providers and ingredient producers showcasing biotechnological solutions in Brussels. European Biotechnology spoke with Dr Gerhard Schmid, Head, Wacker Biosolutions, about the market, challenges, and growth strategies within the bioeconomy.
IL-10R-deficient macrophages trigger IBD
Latest NewsResearchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Breakthrough in liquid biopsy
Latest NewsGerman and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
Lytix Biopharma brings two scientists on board
AppointmentsNobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to join the company as Company Strategic Advisors
ReViral Appoints Alex C. Sapir as CEO
AppointmentsReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).
ADC Therapeutics raise $76m in Series E expansion
Latest NewsSwiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Janssen and Genmab in licence option deal
Latest NewsPatent Ineligibility Initiative
OpinionBy Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The Life Science Industry needs a strong, predictable, reliable patent system that incentivizes innovations in order to bring new drugs and diagnostics to the patient, drives innovations and prevents patent abuse. The US Supreme Court has rendered a series of decisions about patent eligibility (§101 of the Patent Act) that make entire parts of Life Science Technology ineligible for patent protection and/or renders granted patents unenforceable. This makes the patent system unreliable and unpredictable and averse to investment into innovations. Change will need to come from Congress. Recently, a group of Senators and Representatives of the US Congress released the draft text of a bipartisan, bicameral proposal to reform Section 101 of the Patent Act. The initiative to reform Section 101 of the Patent Act needs political support from all life science stakeholders including from those in Biotech.
Paul Hudson to become Sanofi CEO
AppointmentsAt its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.